Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Medlab Clinical receives human ethics approval for cannabis-based pain management medicine trial

Proactive Investors Tuesday, 18 June 2019
Medlab Clinical Ltd (ASX:MDC) has received human ethics approval for the second trial of its cannabis-based medicine NanaBis™. Known as an Observational Study, the data from this study will be used to enhance regulatory package for potential drug approval. The trial will follow how Australian doctors use NanaBis, provide patient feedback and as a result will provide valuable data aimed to support its global regulatory efforts. The cost of the trial will be partly funded by successful participants as they will have access to NanaBis at a significantly reduced price. READ: Medlab Clinical signs second international distribution deal for NanaBis Medlab CEO Dr Sean Hall said: “This trial is very important to us as it allows MDC to leverage the Australian Special Access Scheme (SAS), follow the patients closely, but more-so publish and use the forthcoming data to bolster all our regulatory efforts as it relates to NanaBis. “In talks with a number of regulatory bodies, we were offered a unique ability to use this type of data in an effort to diminish the otherwise prescribed number of people needed to finalise drug application work. “This trial is happening in parallel to the almost completed Royal North Shore (RNS) trial. “With regards to the work at RNS, early data received is very pleasing and this coupled with the learnings from the current Australian SAS usage, NanaBis is a strong contender for pain management and in my mind a viable pain management medication.”   Medlab expects to roll this trial out to 2,000 patients across Australia as quick as possible, making it one of the most significant cannabis trials to date.
0
shares
ShareTweetSavePostSend
 
Credit: Rant Sports - Published < > Embed
News video: Alternatives for Chronic Pain Management in Postherpetic Neuralgia

Alternatives for Chronic Pain Management in Postherpetic Neuralgia 08:36

Shingles affects an estimated 1 million people in the United States each year. The coinciding rash is known to cause severe discomfort. For most, when the rash leaves, the pain goes with it. But for some, the pain persists long after their skin has cleared. It's called postherpetic...

You Might Like


Recent related videos from verified sources

AstraZeneca Talks Drug Pricing, Pipeline, and Path Ahead [Video]AstraZeneca Talks Drug Pricing, Pipeline, and Path Ahead

The pharmaceutical industry is firmly focused on a few key factors as of late: drug prices, M&A action, and the promise of drug pipelines. AstraZeneca , a UK-based manufacturer of numerous popular..

Credit: The Street     Duration: 05:08Published

UPMC Clinical Trial, Pancreatic Cancer Treatment [Video]UPMC Clinical Trial, Pancreatic Cancer Treatment

UPMC is now participating in a clinical trial that involves a new method of pancreatic cancer treatment. Doctors and patients both say the results are promising; KDKA's Lisa Washington reports.

Credit: KDKA CBS 2 Pittsburgh     Duration: 03:15Published

Products For Back And Nick Muscle Tension [Video]Products For Back And Nick Muscle Tension

Chronic back and neck pain can be annoying and sometimes only get worse with age. That's why Sally Kaplan, a writer for Business Insider, made a list of different products that will help. The first..

Credit: Wochit News     Duration: 00:36Published

Pain management doctor in Smyrna using wireless device to help keep patients off opioids [Video]Pain management doctor in Smyrna using wireless device to help keep patients off opioids

Dr. Graf Hilgenhurst has been in the pain management business since 1989.

Credit: NewsChannel 5 Nashville     Duration: 01:36Published


Recent related news from verified sources

Zelda Therapeutics teams up with medicinal cannabis clinic network

Zelda Therapeutics Ltd (ASX:ZLD) has entered into a strategic collaboration agreement with Emerald Clinics to access clinical data from patients treated with...
Proactive Investors Also reported by •GlobeNewswire

Avalon GloboCare launches first-in-human study of AVA-001 for leukemia, non-Hodgkin lymphoma

Avalon GloboCare Corp (NASDAQ:AVCO) on Monday provided an update of four clinical programs in cellular therapy, noting that AVA-001 entered into this month the...
Proactive Investors

Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases

Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases
STRASBOURG, France--(BUSINESS WIRE)--$TNG #OncolyticVirus--Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based...
Business Wire

Propanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock Split

Propanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock Split
MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTC: PPCBD) (“Propanc”), a biopharmaceutical company developing new cancer treatments for...
Business Wire


Other recent news in Business

EQUIFAX to pay up to $700 million in U.S. data breach settlementPresident, PM laud CHANDRAYAAN-2 launch
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.